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Gastric acid-dependent diseases, i.e. gastroesophageal reflux disease and peptic ulcers, are the leading causes of heart
burn, epigastralgia, and dyspeptic symptoms. Gastric acid suppressing intervention have demonstrated a marked reduction
in subjective symptoms as well as ulcer healing. Proton pump inhibitors (PPIs) have been widely used for the treatment of
these diseases and Helicobacter pylori eradication therapy due to their strong anti-secretory effects by inhibiting H+K+-
ATPase of parietal cells [1–3]. Besides the acid-suppressing effects, PPIs, especially lansoprazole, have been shown to
modulate the inflammatory status, reduce oxidative stress, and improve mucosal injury in the small intestine [4, 5]. In vitro
studies have also demonstrated that PPIs inhibit the increased expression of vascular adhesion molecules, the activation of
neutrophils, and the production of pro-inflammatory cytokines [6, 7]. Recent our study using a DNA microarray clearly
indicates that lansoprazole induces several genes including phase II detoxifyingenzymes (NADH-ubiquinone oxidoreductase,
glutathione S-transferase) and antioxidant stress proteins (heme oxygenase 1, thioredoxin reductase, superoxide dismutase)
in gastric epithelial cells. All data are available on the internet (http://www2.kpu-m.ac.jp/%7Efirstmed/GeneChip.html). These
data provide additional perspectives for a possible but yet unexplored use of PPIs, especially lansoprazole, in cytoprotection
and vasoprotection. In this serial review, we invite several outstanding researchers in this field to summarize their work, to
review their peers’ activity, and to encourage us by their opinions. I thank all the anonymous reviewers of these articles for
their insightful comments.
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